[1] 王盼,任立红.特发性炎症性肌病的诊治进展[J].现代医学,2018,46(1):97-100.
[2] BETTERIDGE Z,MCHUGH N.Myositis-specific autoantibodies:an important tool to support diagnosis of myositis[J].J Intern Med,2015,280(1):8-23.
[3] TANSLEY S L,SIMOU S,SHADDICK G,et al.Autoantibodies in juvenile-onset myositis:Their diagnostic value and associated clinical phenotype in a large UK cohort[J].J Autoimmun,2017,84:55-64.
[4] BASHARAT P,CHRISTOPHERSTINE L.Immune-mediated necrotizing myopathy:update on diagnosis and management[J].Curr Rheumatol Rep,2015,17(12):72-84.
[5] PINAL-FERNANDEZ I,PARKS C,WERNER J L,et al.Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle[J].Arthritis Care Res,2017,69(2):263-270.
[6] SUZUKI S,HAYASHI Y K,KUWANA M,et al.Myopathy associated with antibodies to signal recognition particle:disease progression and neurological outcome[J].Arch Neurol,2012,69(6):728-732.
[7] BINNS E L,MORAITIS E,MAILLARD S,et al.Effective induction therapy for anti-SRP associated myositis in childhood:A small case series and review of the literature[J].Pediatr Rheumatol Online J,2017,15(1):77-84.
[8] MAMMEN A L,CHUNG T,CHRISTOPHER-STINE L,et al.Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy[J].Arthritis Rheum,2011,63(6):713-721.
[9] ALLENBACH Y,DROUOT L,RIGOLET A,et al.Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies:inconstant exposure to statin[J].Medicine (Baltimore),2014,93(3):150-157.
[10] MAMMEN A L.Necrotizing myopathies:beyond statins[J].Curr Opin Rheumatol,2014,26(6):679-783.
[11] KISHI T,RIDER L G,PAK K,et al.Association of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients[J].Arthritis Care Res (Hoboken),2017,69(7):1088-1094.
[12] TINIAKOU E,PINAL-FERNANDEZ I,LLOYD T E,et al.More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy[J].Rheumatology (Oxford),2017,56(5):787-794.
[13] HAMAGUCHI Y.Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies:heterogeneity within the syndrome[J].PLoS One,2013,8(4):e60442.
[14] KLEIN M,MANN H,PLEŠTILOVÁ L,et al.Arthritis in idiopathic inflammatory myopathy:clinical features and autoantibody associations[J].J Rheumatol,2014,41(6):1133-1139.
[15] SHI J,LI S,YANG H,et al.Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies[J].J Rheumatol,2017,44(7):1051-1057.
[16] RIDER L G,SHAH M,MAMYROVA G,et al.The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies[J].Medicine (Baltimore),2013,92(4):223-243.
[17] HUBER A M,MAMYROVA G,LACHENBRUCH P A,et al.Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies[J].Arthritis Care Res (Hoboken),2014,66(5):732-740.
[18] UEKI M,KOBAYASHI I,TAKEZAKI S,et al.Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies[J].Mod Rheumatol,2019,29(2):351-356.
[19] FREDI M,BARTOLI F,CAVAZZANA I,et al.Calcinosis in poly-dermatomyositis:clinical and laboratory predictors and treatment options[J].Clin Exp Rheumatol,2017,35(2):303-308.
[20] VALENZUELA A,CHUNG L,CASCIOLA-ROSEN L.Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis[J].JAMA Dermatol,2014,150(4):724-729.
[21] 李鞠,唐凤英,蒋真,等.幼年皮肌炎患者血清脂质水平的临床研究[J].东南大学学报(医学版),2016,35(1):21-25.
[22] HOSHINO K,MURO Y,SUGIURA K,et al.Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis[J].Rheumatology (Oxford),2010,49(4):1726-1733.
[23] MURO Y,SUGIURA K,NARA M,et al.High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis[J].Rheumatology,2015,118(4):1745-1747.
[24] WOLSTENCROFT P W.Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoanti-bodies[J].Curr Rheumatol Rep,2018,20(5):28-39.
[25] FUJIMOTO M,HAMAGUCHI Y,KAJI K,et al.Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins[J].Arthritis Rheum,2012,64(2):513-522.
[26] WANG L,HUANG L,YANG Y,et al.Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay[J].Clin Rheumatol Clin Rheumatol,2018,37(10):2731-2739.
[27] KOBAYASHI I,OKURA Y,YAMADA M,et al.Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis[J].J Pediatr,2011,158(4):675-677.
[28] SATO S,HOSHINO K,SATOH T,et al.RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis:Association with rapidly progressive interstitial lung disease[J].Arthritis Rheum,2009,60(7):2193-2200.
[29] KOBAYASHI N,TAKEZAKI S,KOBAYASHI I,et al.Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis[J].Rheumatology (Oxford),2015,54(4):784-791.
[30] HALL J C,CASCIOLA-ROSEN L,SAMEDY L A,et al.Anti-melanoma differentiation-associated protein 5-associated dermatomyositis:expanding the clinical spectrum[J].Arthritis Care Res (Hoboken),2013,65(8):1307-1315.
[31] WATANABE K,HANDA T,TANIZAWA K,et al.Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias[J].Respir Med,2011,105(8):1238-1247.
[32] AGGARWAL R,MCBURNEY C,SCHNEIDER F,et al.Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis[J].Rheumatology,2017,56(3):384-389.
[33] AGGARWAL R,CASSIDY E,FERTIG N,et al.Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients[J].Ann Rheum Dis,2014,73(1):227-2 |
